Q-omics provides the consensus-scored CASP12 profile across patient tissues and cancer cell-line models. CASP12 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CASP12 is differentially expressed in 16, with the highest sampling consensus in LUAD. Additionally, CASP12 RNA expression shows 20,152 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, LUAD, and LSCC as cancer lineages where CASP12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CASP12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CASP12 survival associations across molecular data types. CASP12 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CASP12 RNA expression–survival associations across cancer types. High CASP12 expression shows unfavorable associations in UVM and KIRP, but favorable associations in HNSC, LUAD, KIRC and LIHC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for CASP12 RNA expression.
This table summarizes CASP12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for CASP12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CASP12 shows lower tumor expression in LUAD, BLCA, LUSC, THCA and COAD and higher tumor expression in KIRC. The LUAD box plot shows higher CASP12 RNA expression in normal versus tumor tissue (log2 FC = −1.535, t-test p < 0.001).
This table shows molecular features associated with CASP12 in patient tissues and cancer cell lines. In patient samples, CASP12 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CASP12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and SKIN.
